{{Rsnum
|rsid=6275
|Gene=DRD2
|Chromosome=11
|position=113412755
|Orientation=minus
|ReferenceAllele=T
|GMAF=0.4729
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=DRD2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 42.5 | 48.7 | 8.8
| HCB | 22.6 | 46.7 | 30.7
| JPT | 23.9 | 48.7 | 27.4
| YRI | 10.9 | 35.4 | 53.7
| ASW | 17.5 | 54.4 | 28.1
| CHB | 22.6 | 46.7 | 30.7
| CHD | 17.4 | 56.0 | 26.6
| GIH | 31.7 | 51.5 | 16.8
| LWK | 3.6 | 38.2 | 58.2
| MEX | 53.4 | 39.7 | 6.9
| MKK | 8.3 | 42.3 | 49.4
| TSI | 54.9 | 39.2 | 5.9
| HapMapRevision=28
}}
{{PMID|19207030}} [[rs6275]]/DRD2 and [[rs4680]]/COMT useful in predicting disease risk among [[schizophrenia]] patients

See also [[rs6277]].

{{ neighbor
| rsid = 6277
| distance = 18
}}
{{ neighbor
| rsid = 1801028
| distance = 7
}}

{{PMID Auto
|PMID=19373123
|Title=Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution
}}

{{PMID Auto
|PMID=18838251
|Title=Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia
}}

{{PharmGKB
|RSID=rs6275
|Name_s=
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:19373123
|Annotation=Risk or phenotype-associated allele: T. Phenotype: The average and maximum daily methadone doses were significantly associated with the DRD2 rs6275C>T SNP (P=0.016 and 0.005 for average and maximum dose, respectively). Carriers of the variant rs6275T allele needed higher methadone doses than noncarriers. Study size: 85. Study population/ethnicity: Caucasian. Type of association: GN.
|Drugs=methadone
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165109703
}}

{{PMID Auto
|PMID=19512960
|Title=Genetic diagnostics of functional variants of the human dopamine D2 receptor gene
}}

{{PharmGKB
|RSID=rs6275
|Name_s=
|Gene_s=DRD2
|Feature=
|Evidence=PubMed ID:19207030
|Annotation=This variant (rs6275/DRD2) along with rs4680/COMT are associated with risk for schizophrenia in a study consisting of 254 patients and 225 controls of southern indian origin.
|Drugs=
|Drug Classes=
|Diseases=Psychotic Disorders; Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA162630416
}}

{{PMID Auto
|PMID=21095016
|Title=Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women
}}

{{PMID Auto
|PMID=16867246
|Title=Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.
}}

{{PMID Auto
|PMID=18077373
|Title=Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.
|OA=1
}}

{{PMID Auto
|PMID=18154681
|Title=A lesson not learned: allele misassignment.
|OA=1
}}

{{PMID Auto
|PMID=18305461
|Title=Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety.
|OA=1
}}

{{PMID Auto
|PMID=18477981
|Title=[The association study of the DRD2 gene C939T polymorphism and schizophrenia.]
}}

{{PMID Auto
|PMID=18698231
|Title=Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues.
|OA=1
}}

{{PMID Auto
|PMID=18829695
|Title=Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia.
|OA=1
}}

{{PMID Auto
|PMID=19197363
|Title=A genome-wide investigation of SNPs and CNVs in schizophrenia.
|OA=1
}}

{{PMID Auto
|PMID=19590515
|Title=Association between dopaminergic genes (SLC6A3 and DRD2) and stuttering among Han Chinese.
}}

{{PMID Auto
|PMID=19772578
|Title=Two-stage case-control association study of dopamine-related genes and migraine.
|OA=1
}}

{{PMID Auto
|PMID=19911060
|Title=Persistence criteria for susceptibility genes for schizophrenia: a discussion from an evolutionary viewpoint.
|OA=1
}}

{{PMID Auto
|PMID=19913597
|Title=An association study of DRD2 gene polymorphisms with schizophrenia in a Chinese Han population.
}}

{{PMID Auto
|PMID=20191112
|Title=The Genetics of Anorexia Nervosa: Current Findings and Future Perspectives.
|OA=1
}}

{{PMID Auto
|PMID=21354244
|Title=The role of dopamine transporter (SLC6A3) and dopamine D2 receptor/ankyrin repeat and kinase domain containing 1 (DRD2/ANKK1) gene polymorphisms in personality traits.
}}

{{PMID Auto
|PMID=22290307
|Title=Predictive index for the onset of medication overuse headache in migraine patients.
}}

{{PMID Auto
|PMID=22615781
|Title=Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6275
|overall_frequency_n=6393
|overall_frequency_d=10758
|overall_frequency=0.594255
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=62
|n_articles=2
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=22875483
|Title=Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility.
}}

{{PMID Auto
|PMID=22970887
|Title=The association between DRD2/ANKK1 and genetically informed measures of alcohol use and problems.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}